Modeling Alzheimer's risk using human TREM2-knockout microglia
Amanda McQuade from Dr. Mathew Blurton-Jones’s lab discusses her protocol for differentiating microglia from induced pluripotent stem cells (iPSCs) and the use of these microglia in vivo and in vitro to uncover the mechanisms of immune activation and neurodegeneration in Alzheimer’s disease.
Amanda McQuade from Dr. Mathew Blurton-Jones’s lab discusses her protocol for differentiating microglia from induced pluripotent stem cells (iPSCs) and the use of these microglia in vivo and in vitro to uncover the mechanisms of immune activation and neurodegeneration in Alzheimer’s disease. Based on the 2020 Nature Communications paper "Gene Expression and Functional Deficits Underlie TREM2-Knockout Microglia Responses in Human Models of Alzheimer’s Disease"
Publish Date:
February 11, 2021
Related Multimedia
-
How to Count hPSC Aggregates to Determine Plating Density for Maintenance and Differentiation
Publish Date: October 14, 2019 -
STEMCELL Journal Club: Patient-Derived Alzheimer’s Disease Modeling
Publish Date: May 25, 2020 -
Engineering the Hematopoietic System to Treat Non-Hematological Disorders
Publish Date: February 03, 2020
Explore Our Products
-
Defined supplement for single-cell cloning of human ES and iPS cells -
STEMdiff™ Microglia Differentiation Kit
Differentiation kit for the generation of microglia precursors from human ES and iPS cell-derived hematopoietic progenitor cells -
STEMdiff™ Microglia Maturation Kit
Maturation kit for the generation of microglia from human ES and iPS cell-derived microglia precursors -
Feeder-free, animal component-free culture medium for maintenance of human ES and iPS cells
